Clinical experiences with systemically administered siRNA-based therapeutics in cancer (Q38633261)

5 September 2017

title

Clinical experiences with systemically administered siRNA-based therapeutics in cancer (English)

1 reference

5 September 2017

Jonathan E Zuckerman

1

1 reference

5 September 2017

Mark E Davis

series ordinal

2

1 reference

5 September 2017

publication date

16 November 2015

1 reference

Nature Reviews Drug Discovery

5 September 2017

published in

1 reference

5 September 2017

volume

14

1 reference

5 September 2017

issue

12

1 reference

5 September 2017

page(s)

843-856

1 reference

Gene silencing by double-stranded RNA (Nobel Lecture).

5 September 2017

cites work

1 reference

RNA-based therapeutics: current progress and future prospects.

31 March 2020

1 reference

A status report on RNAi therapeutics

31 March 2020

1 reference

Interfering with disease: a progress report on siRNA-based therapeutics

31 March 2020

1 reference

Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides

31 March 2020

1 reference

Knocking down barriers: advances in siRNA delivery

31 March 2020

1 reference

Potential clinical applications of siRNA technique: benefits and limitations

31 March 2020

1 reference

RNA interference in the clinic: challenges and future directions

31 March 2020

1 reference

RNAi therapies: drugging the undruggable

31 March 2020

1 reference

Nanoparticle therapeutics: an emerging treatment modality for cancer

31 March 2020

1 reference

Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.

31 March 2020

1 reference

Delivery materials for siRNA therapeutics

31 March 2020

1 reference

Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology

31 March 2020

1 reference

Chemical modification of siRNAs for in vivo use.

31 March 2020

1 reference

Progress toward in vivo use of siRNAs-II

31 March 2020

1 reference

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

31 March 2020

1 reference

Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles

31 March 2020

1 reference

Development of siRNA payloads to target KRAS-mutant cancer

31 March 2020

1 reference

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia

31 March 2020

1 reference

siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury

31 March 2020

1 reference

Strategies in the design of nanoparticles for therapeutic applications

31 March 2020

1 reference

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

31 March 2020

1 reference

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

31 March 2020

1 reference

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing

31 March 2020

1 reference

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

31 March 2020

1 reference

Antisense therapeutics in oncology: current status

31 March 2020

1 reference

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

31 March 2020

1 reference

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

31 March 2020

1 reference

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

31 March 2020

1 reference

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.

31 March 2020

1 reference

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

31 March 2020

1 reference

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

31 March 2020

1 reference

The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

31 March 2020

1 reference

Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways

31 March 2020

1 reference

Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo

31 March 2020

1 reference

Safety profile of RNAi nanomedicines

31 March 2020

1 reference

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

31 March 2020

1 reference

Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses

31 March 2020

1 reference

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

31 March 2020

1 reference

Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals

31 March 2020

1 reference

Nanoparticle hydrophobicity dictates immune response

31 March 2020

1 reference

Stability study of unmodified siRNA and relevance to clinical use.

31 March 2020

1 reference

Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing

31 March 2020

1 reference

siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide

31 March 2020

1 reference

Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities

31 March 2020

1 reference

Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma

31 March 2020

1 reference

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

31 March 2020

1 reference

Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency.

31 March 2020

1 reference

Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors

31 March 2020

1 reference

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

31 March 2020

1 reference

Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.

31 March 2020

1 reference

In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier

31 March 2020

1 reference

Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs

31 March 2020

1 reference

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

31 March 2020

1 reference

Cancer nanomedicines: so many papers and so few drugs!

31 March 2020

1 reference

Therapeutic oligonucleotides: the road not taken

31 March 2020

1 reference

31 March 2020

1 reference

The dicey role of Dicer: implications for RNAi therapy

31 March 2020

1 reference

Dicer, Drosha, and outcomes in patients with ovarian cancer

31 March 2020

1 reference

Prognostic significance of deregulated dicer expression in breast cancer

31 March 2020

1 reference

Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer

31 March 2020

1 reference

MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.

31 March 2020

1 reference

31 March 2020

1 reference

Genome editing. The new frontier of genome engineering with CRISPR-Cas9

31 March 2020

1 reference

Investigating the optimal size of anticancer nanomedicine.

31 March 2020

1 reference

Heterogeneity in nanoparticles influences biodistribution and targeting

31 March 2020

1 reference

Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance

31 March 2020

1 reference

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics

31 March 2020

1 reference

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.

31 March 2020

1 reference

Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates

31 March 2020

1 reference

Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo

31 March 2020

1 reference

Toxicity profiling of several common RNAi-based nanomedicines: a comparative study

31 March 2020

1 reference

Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model

31 March 2020

1 reference

Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery

31 March 2020

1 reference

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size

31 March 2020

1 reference

Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology

31 March 2020

1 reference

Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer

31 March 2020

1 reference

Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates.

31 March 2020

1 reference

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

31 March 2020

1 reference

Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models

31 March 2020

1 reference

Tissue-specific gene silencing monitored in circulating RNA.

31 March 2020

1 reference

Long-distance communication between laryngeal carcinoma cells

31 March 2020

1 reference

Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis

31 March 2020

1 reference

Intercellular communication by exosome-derived microRNAs in cancer

31 March 2020

1 reference

Vesicle trafficking and RNA transfer add complexity and connectivity to cell-cell communication

31 March 2020

1 reference

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

31 March 2020

1 reference

Epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

Beyond BRAF: where next for melanoma therapy?

31 March 2020

1 reference

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26567702

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26567702

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD4685

1 reference

5 September 2017

1 reference